Scarica l'app Stockscreener
19.45
0.26%
-0.05
Dopo l'orario di chiusura:
19.69
0.24
+1.23%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARWR Giù?
Forum
Previsione
Frazionamento azionario
Arrowhead Pharmaceuticals Inc Borsa (ARWR) Ultime notizie
Insider Selling: Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Sells 26,712 Shares of Stock - MarketBeat
Arrowhead Pharmaceuticals CEO sells $567,485 in stock By Investing.com - Investing.com UK
Ionis To Get Head Start On Arrowhead With Tryngzola Launch - Citeline News & Insights
HC Wainwright Reaffirms Buy Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR) - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Raised to Sell at StockNews.com - MarketBeat
Arrowhead Pharma Approves Major Employee Stock Grants, Expands Workforce with 20 New Hires - StockTitan
Arrowhead Pharmaceuticals director sells shares totaling $121,555 By Investing.com - Investing.com Canada
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Director William D. Waddill Sells 3,748 Shares - MarketBeat
Arrowhead Pharmaceuticals director sells $164,665 in stock - Investing.com India
Arrowhead Pharmaceuticals director sells $164,665 in stock By Investing.com - Investing.com South Africa
Arrowhead Pharmaceuticals director sells shares totaling $121,555 - Investing.com
Arrowhead Pharmaceuticals director Victoria Vakiener sells $197,058 in stock - Investing.com
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives $42.70 Average PT from Brokerages - MarketBeat
Research Analysts Set Expectations for ARWR Q2 Earnings - MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Short Interest Update - MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Purchased by State Street Corp - MarketBeat
Arrowhead Pharmaceuticals' SWOT analysis: RNAi pioneer's stock faces pivotal year - Investing.com
Jane Street Group LLC Reduces Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat
(ARWR) Technical Pivots with Risk Controls - Stock Traders Daily
Chardan Capital Reiterates Buy Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR) - MarketBeat
Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases - BioSpace
Hypercholesterolemia Pipeline 2024: Clinical Trials - openPR
Arrowhead Pharma Shares See Big Price Jump - Los Angeles Business Journal
Shareholders in Arrowhead Pharmaceuticals (NASDAQ:ARWR) have lost 66%, as stock drops 9.3% this past week - Yahoo Finance
What is HC Wainwright's Estimate for ARWR Q1 Earnings? - MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Purchased by Verition Fund Management LLC - MarketBeat
Research Analysts Issue Forecasts for ARWR Q2 Earnings - MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by Fmr LLC - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 135,904 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat
Erste Asset Management GmbH Acquires New Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity - The Bakersfield Californian
Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences - BioSpace
(ARWR) Trading Advice - Stock Traders Daily
Arrowhead, Sarepta Stocks Rise Despite Price-Target Cuts Post $1B Licensing Deal: Retail Buzz Strong - MSN
Intech Investment Management LLC Takes Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat
Fisher Asset Management LLC Grows Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target Cut to $24.00 by Analysts at Sanford C. Bernstein - MarketBeat
Arrowhead price target lowered to $24 from $27 at Bernstein - Yahoo Finance
Deal Watch: Sarepta Targets RNAi In Broad Collaboration With Arrowhead - News & Insights
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2024 Earnings Call Transcript - Insider Monkey
Antisense & RNAi Therapeutics Global Market Report 2024 To 2033 | - openPR
Arrowhead Pharmaceuticals Faces Distribution Risks with Vanscoy Reliance - Yahoo Finance
Arrowhead Pharmaceuticals’ Lincense Collaboration Agreement with Sarepta Therapeutics - Global Legal Chronicle
Arrowhead: The Sarepta Partnership Validates RNAi Platform And Reduces Risk (NASDAQ:ARWR) - Seeking Alpha
Insiders Sold US$1.6m Of Arrowhead Pharmaceuticals Stock Possibly Sending Warning Sign - Simply Wall St
Sarepta Therapeutics licenses programs from Arrowhead Pharmaceuticals - BioWorld Online
Arrowhead Stock Rockets 16% After Major Licensing Deal - GuruFocus.com
Earnings call: Arrowhead Pharmaceuticals reports transformative year By Investing.com - Investing.com South Africa
Earnings call: Arrowhead Pharmaceuticals reports transformative year - Investing.com India
Chardan Capital Reaffirms Buy Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR) - MarketBeat
Sarepta rebuilds drug pipeline with Arrowhead deal - Yahoo Finance
Arrowhead and Sarepta link for rare genetic disease treatments - Pharmaceutical Technology
Arrowhead Pharmaceuticals Inc (ARWR) Q4 2024 Earnings Call Highl - GuruFocus.com
Arrowhead Pharmaceuticals Inc (ARWR) Q4 2024 Earnings Call Highlights: Transformational ... By GuruFocus - Investing.com Canada
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):